Lipocine Inc. (LPCN)

Sorry, no known transcripts

Recent filings

Notice of exempt solicitation submitted by non-management - May 20, 2020

Lipocine Announces Presentations On Tlando™ At Aua Virtual Experience 2020 - May 15, 2020

Lipocine: Treatment Potential Of Lpcn 1144 Demonstrated In A Pre-Clinical Nash And Hepatic Fibrosis Model - May 13, 2020

Lipocine: Tlando™ Fixed Dose Oral Trt - May 11, 2020

Lipocine Inc. Just Filed Its Quarterly Report: (2)   Earnings (L... - May 7, 2020

Lipocine: Salt Lake City, May 7, 2020 – - May 7, 2020

Lipocine: Fda Clears Lpcn 1148 Ind Application For Phase 2 Cirrhosis Trial - May 5, 2020

Other definitive proxy statements - April 28, 2020

As previously disclosed on its Current Report on Form - April 21, 2020

Lipocine: U.S. Fda Denies Clarus’S Oral Testosterone Ester Citizen Petition - April 17, 2020

Lipocine Inc. just filed a prospectus, suggesting it plans to soon issue some securities - April 10, 2020

Lipocine Announces Us Court Of Appeals For The Federal Circuit Affirms Decision Of Uspto - April 9, 2020

Lipocine: Impact Of A New Oral Testosterone Undecanoate On Blood Pressure And Cardiovascular Risk Introduction: - April 1, 2020

Current report, items 8.01 and 9.01 - March 26, 2020

Lipocine Inc. director just picked up 220,000 shares - March 18, 2020

Lipocine Announces 2019 Year End Financial And Operational Results - March 13, 2020

Lipocine Inc. Just Filed Its Annual Report: (j)    Earnings (... - March 13, 2020

Lipocine Announces Tlando™ Pdufa Date Of August 28, 2020 - March 4, 2020

Lipocine Announces Closing Of Registered Direct Offering Of Common Stock And Warrants - Feb. 27, 2020

Entry into a Material Definitive - Feb. 26, 2020

Lipocine Inc. just filed a prospectus, suggesting it plans to soon issue some securities - Feb. 26, 2020

Sabby Volatility Warrant Master Fund, Ltd. just provided an update on share ownership of Lipocine Inc. - Feb. 25, 2020

Lipocine Announces $6 Million Registered Direct Offering Priced At-The-Market - Feb. 25, 2020

Lipocine Announces Regulatory Path Forward For Tlando™ Resubmission - Feb. 24, 2020

Renaissance Technologies LLC just provided an update on share ownership of Lipocine Inc. - Feb. 12, 2020

Lipocine Streamlines Its Infringement Lawsuit Against Clarus Therapeutics - Feb. 11, 2020

Sander Gerber just provided an update on share ownership of Lipocine Inc. - Feb. 6, 2020

Lipocine: A Novel Oral Testosterone Therapy (Tlando) Safely Restores Testosterone To Eugonadal Levels With Fixed Dose Treatment Author Block: - Feb. 5, 2020

Lipocine Inc.'s CEO and President was just granted 300,000 options - Jan. 28, 2020

Lipocine Inc.'s EVP and CFO was just granted 132,000 options - Jan. 28, 2020

Sabby Volatility Warrant Master Fund, Ltd. just provided an update on share ownership of Lipocine Inc. - Jan. 14, 2020

Lipocine: Enabling Oral Drug Delivery To Improve Patient Compliance Lpcn 1144 For Pre - Cirrhotic Nash - Jan. 13, 2020

Lipocine: Lpcn 1144 (Oral Testosterone Undecanoate) Resolves Non-Alcoholic Fatty Liver Disease Michael Charlton - Jan. 10, 2020

Lipocine Inc.'s CEO and President just picked up 40,000 shares - Jan. 2, 2020

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or - Dec. 27, 2019

Lipocine Inc.'s President and CEO just picked up 25,000 shares - Dec. 10, 2019

Lipocine Inc.'s CEO and President just picked up 101,500 shares - Dec. 6, 2019

Lipocine Inc.'s EVP and Chief Financial Office just picked up 40,250 shares - Dec. 6, 2019

Lipocine Inc.'s President and CEO just picked up 25,000 shares - Nov. 26, 2019

Sabby Volatility Warrant Master Fund, Ltd. just provided an update on share ownership of Lipocine Inc. - Nov. 22, 2019

Lipocine Inc.'s CEO and President just picked up 50,000 shares - Nov. 18, 2019

Lipocine Announces Closing Of Public Offering Of Common Stock And Warrants - Nov. 18, 2019

Lipocine Inc. just filed a prospectus, suggesting it plans to soon issue some securities - Nov. 15, 2019

Lipocine Announces Pricing Of Public Offering Of Common STOCK AND WARRANTS - Nov. 14, 2019

As previously - Nov. 14, 2019

Lipocine Inc. just filed a prospectus, suggesting it plans to soon issue some securities - Nov. 14, 2019

Lipocine Inc. just filed a prospectus, suggesting it plans to soon issue some securities - Nov. 13, 2019

Lipocine Announces Launch Of Public Offering Of Common Stock And Warrants - Nov. 13, 2019

Lipocine Announces Third Quarter 2019 Financial And Operational Results - Nov. 12, 2019

Lipocine Receives Complete Response Letter For Tlando™ From U.S. FDA - Nov. 12, 2019

Lipocine Inc. Just Filed Its Quarterly Report: (2)   Earnings (L... - Nov. 12, 2019

Regulation FD - Nov. 8, 2019

Lipocine Inc. just filed a prospectus, suggesting it plans to soon issue some securities - Nov. 7, 2019

The Company will make an oral presentation at the - Oct. 25, 2019

On October - Oct. 21, 2019

The Company will make several presentations at the - Oct. 21, 2019

Lipocine: Lpcn 1144 Resolves Non-Alcoholic Fatty Liver Disease Somaya Albhaisi - Oct. 1, 2019

First Biopsy Confirmed Nash Patient Dosed In Lipocine STUDY OF LPCN 1144 - Sept. 30, 2019

Lipocine: Tlando (Lpcn 1144) Reduces Liver Fat In Men With Fatty Liver Irwin Goldstein ; Kilyoung Kim - Sept. 23, 2019

Lipocine: Antares Pharma Presentation At Jefferies 2019 Healthcare Conference Trx = Total Prescriptions Current Promotional Spend At An All - Time Low - Sept. 23, 2019

Lipocine Announces Trial Date In Lipocine’S Infringement Lawsuit Against Clarus - Aug. 27, 2019

Lipocine Inc. Just Filed Its Quarterly Report:     ... - Aug. 7, 2019

Lipocine Announces Second Quarter 2019 Financial And Operational Results - Aug. 7, 2019

Current report, items 7.01, 8.01, and 9.01 - July 23, 2019

Lipocine Set To Join Russell Microcap® Index - June 25, 2019

Departure of Directors or Certain - June 24, 2019

Lipocine Inc. director was just granted 10,000 options - June 14, 2019

Lipocine Inc. director was just granted 10,000 options - June 14, 2019

Lipocine Inc. director was just granted 10,000 options - June 14, 2019

Lipocine Inc. director was just granted 10,000 options - June 14, 2019

Submission of Matters to a Vote of Security - June 12, 2019

Lipocine: 15 Targeted For Testosterone Replacement Therapy Annual Trx ~7M - May 28, 2019

Lipocine Inc.'s President and CEO just picked up 10,000 shares - May 28, 2019

Notice of exempt solicitation submitted by non-management - May 22, 2019

Lipocine: The Nasdaq Stock Market Llc Outstanding Shares - May 15, 2019

Lipocine Announces Tlando™ Nda Pdufa Action Date Of November 9, 2019 - May 14, 2019

Lipocine Announces First Quarter 2019 Financial And Operational Results - May 8, 2019

Lipocine Inc. Just Filed Its Quarterly Report:  March 31, 2019 Amor... - May 8, 2019

Current report, items 8.01 and 9.01 - May 1, 2019

Lipocine Inc. releases salary data. CEO sees compensation fall -8% - April 30, 2019

Lipocine: The International Liver Congress 2019 Presentation - April 11, 2019

Lipocine Seeks Injunction Against The Marketing Of Clarus Therapeutics’ Jatenzo® For Testosterone Replacement Therapy - April 3, 2019

Lipocine: 16 For Treatment Of Nash Cirrhosis - March 28, 2019

Lipocine Announces Abpm Labeling Study Results Consistent With Recently Approved Testosterone Replacement Therapy - March 27, 2019

Lipocine Late-Breaker Presentation At Easl Meeting To Detail Lpcn 1144 Mri-Pdff Based Clinical Results On Reduction Of Liver Fat And Key Serum Biomarkers - March 26, 2019

Lipocine: 5 Targeted For Testosterone Replacement Therapy - March 18, 2019

Lipocine’S Lpcn 1144 For Nash Demonstrates Substantial Fatty Liver - March 12, 2019

Lipocine: Therapeutic Potential Of Lpcn 1144 In Nafld/Nash - March 7, 2019

Lipocine Inc. Just Filed Its Annual Report: (j) Earnings (Loss) ... - March 6, 2019

Lipocine Announces Financial And Operational Results For The Year Ended December 31, 2018 - March 6, 2019

Lipocine Inc. Announces Fda Clearance Of Ind To Commence Phase 2 Study Of Lpcn 1144 In Biopsy Confirmed Nash Subjects - Feb. 14, 2019

Current report, items 8.01 and 9.01 - Jan. 28, 2019

Lipocine Files Ind To Evaluate Lpcn 1144 In Biopsy Confirmed Nash Subjects - Jan. 24, 2019

The Company made a presentation of LPCN 1144 data at the Keystone Symposia on Integrated Pathways of Disease in NASH and NAFLD Conference in Santa - Jan. 22, 2019

Lipocine’S Nash Therapy Candidate Achieves Meaningful Liver Fat Reduction Based On Interim Results - Jan. 17, 2019

Uspto Grants Priority Motion To Lipocine And Enters Judgment Against Clarus - Jan. 14, 2019

Current report, items 8.01 and 9.01 - Jan. 7, 2019

Lipocine: Conversion Assessment Of Tlando™ - Dec. 31, 2018

Lipocine Announces Lpcn 1144 Clinical Trial Results Selected For Presentation At 2019 Nash-Tag Conference - Dec. 21, 2018

Lipocine Announces Lpcn 1144 Mri-Pdff Clinical Results Selected For Presentation At Keystone Symposia On Integrated Pathways Of Disease In Nash And Nafld - Dec. 20, 2018

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. VHCP Management, LLC 849,921 5.5 Dec. 31, 2016
2. Ameriprise Financial Inc 790,029 N/A March 31, 2020
3. VANGUARD GROUP INC 555,868 N/A June 30, 2019
4. BlackRock Fund Advisors 465,599 N/A Sept. 30, 2016
5. BlackRock Institutional Trust Company, N.A. 365,851 N/A Dec. 31, 2016
6. Del Mar Asset Management, LP 330,683 N/A Sept. 30, 2014
7. RENAISSANCE TECHNOLOGIES LLC 275,114 N/A March 31, 2020
8. GEODE CAPITAL MANAGEMENT, LLC 199,792 N/A March 31, 2020
9. Russell Frank Co/ 90,476 N/A Sept. 30, 2015
10. GROUP ONE TRADING, L.P. 67,017 N/A Dec. 31, 2019
11. RSM US WEALTH MANAGEMENT LLC 65,212 N/A March 31, 2020
12. BlackRock Investment Management, LLC 62,520 N/A Dec. 31, 2016
13. MORGAN STANLEY 57,429 N/A Dec. 31, 2016
14. MILLENNIUM MANAGEMENT LLC 56,537 N/A March 31, 2020
15. FORT PITT CAPITAL GROUP, LLC 51,750 N/A March 31, 2020
16. NORTHERN TRUST CORP 51,017 N/A June 30, 2018
17. NORTHERN TRUST CORP 50,817 N/A March 31, 2019
18. CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 46,000 N/A March 31, 2020
19. NORTHERN TRUST CORP 43,416 N/A March 31, 2018
20. GROUP ONE TRADING, L.P. 32,749 N/A March 31, 2020
21. JPMORGAN CHASE & CO 22,616 N/A Sept. 30, 2017
22. SUSQUEHANNA INTERNATIONAL GROUP, LLP 22,257 N/A June 30, 2019
23. Geduld E E 15,000 N/A Dec. 31, 2016
24. State Street Corp 12,400 N/A March 31, 2020
25. SUSQUEHANNA INTERNATIONAL GROUP, LLP 11,061 N/A March 31, 2020
26. LADENBURG THALMANN FINANCIAL SERVICES INC 10,828 N/A Sept. 30, 2017
27. Virtu Financial LLC 10,720 N/A Dec. 31, 2019
28. BlackRock Advisors LLC 10,155 N/A Sept. 30, 2016
29. Private Advisor Group, LLC 10,000 N/A March 31, 2020
30. CITIGROUP INC 3,447 N/A Sept. 30, 2017

Lipocine Inc. (LPCN)

140
 


Feedback